| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.068 | 0.2 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | JQ-1:vorinostat (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.057 | 0.2 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.037 | 0.2 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |